Summary by Moomoo AI
On June 26, 2024, Novo Nordisk A/S, a leading global healthcare company, announced the termination of the CLARION-CKD phase 3 trial, which was evaluating ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease. The decision to stop the trial came after an independent data monitoring committee concluded that the trial did not meet its primary endpoint during a prespecified interim analysis. As a result, Novo Nordisk will recognize an impairment loss of approximately DKK 5.7 billion, which is expected to negatively impact operating profit growth by about 6 percentage points for the year 2024. This financial impact is in comparison to the operating profit outlook previously communicated for the first quarter of 2024. The company, which acquired ocedurenone from KBP Biosciences PTE., Ltd. in 2023, is now evaluating the further development of ocedurenone for other indications. Novo Nordisk will disclose its financial results for the first half of 2024 and update its financial outlook for the full year on August 7, 2024.